Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.17 Analyst target: $10.00 Upside: 5831.20%
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using a modified vaccinia ankara virus-like particle vaccine platform. The company is headquartered in Smyrna, Georgia.
See the full interactive analysis & chart →Informational only — not investment advice.